Anti-Alzheimer's disease drug development target on Tau
- VernacularTitle:靶向Tau蛋白的抗阿尔茨海默病药物研究进展
- Author:
Tian-yi ZHANG
1
;
Shan-he QU
1
;
Wen-fei WANG
1
;
Zhao ZHANG
1
;
Shi-feng CHU
1
Author Information
- Publication Type:Journal Article
- Keywords: Alzheimer's disease; Tau protein; hyperphospho-rylation; protein aggregation; immunotherapy; artificial intelli-gence
- From: Chinese Pharmacological Bulletin 2025;41(12):2212-2218
- CountryChina
- Language:Chinese
- Abstract: Alzheimer's disease(AD)is the most common cause of cognitive impairment in the elderly,and the formation of intracellular neurofibrillary tangles(NFT)due to the hyperphos-phorylation of Tau is one of its important pathological features.Compared to β-amyloid,the hyperphosphorylation of Tau and the resulting NFT are more closely related to the decline in cognitive ability.This review focuses on anti-AD drugs targeting Tau,em-phasizing the latest progress in inhibiting the hyperphosphoryla-tion of Tau protein,alleviating the aggregation of Tau protein,re-ducing the cytoskeletal damage caused by the hyperphosphoryla-tion of Tau protein by stabilizing microtubules,and immunothera-py,in the hope of providing new insights into drug research for AD and related cognitive disorders associated with Tau protein.
